Skip to main content

Table 2 Hazard ratios and 95% confidence intervals of all-cause mortality by quartiles of serum uric acid variability (measured by CV)

From: Visit-to-visit variability of serum uric acid measurements and the risk of all-cause mortality in the general population

Variable

Quartile 1

Quartile 2

Quartile 3

Quartile 4

Per-SD increase

Ptrend

Overall

 No. of cases

592 (4.29)

606 (4.49)

689 (5.11)

841 (6.24)

  

 Incidence ratea

6.71 (6.20–7.26)

6.84 (6.33–7.40)

7.81 (7.26–8.40)

8.19 (7.63–8.80)

  

 Model 1

Reference

1.03 (0.93–1.16)

1.22 (1.10–1.36)

1.40 (1.26–1.56)

1.14 (1.10–1.18)

< 0.0001

 Model 2

Reference

1.03 (0.92–1.15)

1.20 (1.08–1.34)

1.34 (1.20–1.49)

1.12 (1.08–1.16)

< 0.0001

 Model 3

Reference

1.03 (0.92–1.15)

1.20 (1.08–1.34)

1.33 (1.20–1.49)

1.12 (1.08–1.15)

< 0.0001

 Sensitivity analysisb

Reference

1.00 (0.88–1.13)

1.15 (1.02–1.30)

1.25 (1.10–1.42)

1.10 (1.05–1.15)

< 0.0001

 Sensitivity analysisc

Reference

1.01 (0.89–1.14)

1.16 (1.03–1.31)

1.33 (1.18–1.49)

1.12 (1.07–1.16)

< 0.0001

 Sensitivity analysisd

Reference

1.03 (0.92–1.15)

1.19 (1.06–1.32)

1.30 (1.07–1.45)

1.10 (1.06–1.15)

< 0.0001

Baseline SUA < 300 μmol/L

 No. of cases

301 (4.14)

311 (3.93)

371 (4.32)

450 (5.14)

  

 Incidence ratea

6.02 (5.38–6.74)

5.71 (5.11–6.38)

6.29 (5.68–6.96)

7.51 (6.84–8.23)

  

 Model 1

Reference

1.00 (0.85–1.17)

1.11 (0.96–1.30)

1.34 (1.16–1.55)

1.13 (1.07–1.19)

< 0.0001

 Model 2

Reference

1.00 (0.85–1.17)

1.10 (0.95–1.29)

1.33 (1.14–1.54)

1.15 (1.08–1.22)

< 0.0001

 Model 3

Reference

1.01 (0.86–1.19)

1.13 (0.97–1.31)

1.38 (1.18–1.61)

1.15 (1.08–1.21)

< 0.0001

 Sensitivity analysisb

Reference

1.01 (0.86–1.18)

1.12 (0.96–1.31)

1.31 (1.11–1.54)

1.13 (1.06–1.20)

< 0.0001

 Sensitivity analysisc

Reference

1.01 (0.89–1.14)

1.16 (1.03–1.31)

1.33 (1.18–1.49)

1.15 (1.08–1.22)

< 0.0001

 Sensitivity analysisd

Reference

0.99 (0.84–1.16)

1.10 (0.94–1.28)

1.31 (1.12–1.53)

1.13 (1.07–1.20)

< 0.0001

Baseline SUA ≥ 300 μmol/L

Reference

1.01 (0.85–1.20)

1.12 (0.95–1.32)

1.35 (1.14–1.60)

1.12 (1.06–1.20)

< 0.0001

No. of cases

319 (5.12)

321 (5.75)

349 (7.12)

306 (6.45)

  

Incidence ratea

7.52 (6.74–8.39)

8.48 (7.60–9.46)

10.50 (9.49–11.70)

9.47 (8.46–10.60)

  

Model 1

Reference

1.07 (0.92–1.25)

1.36 (1.17–1.58)

1.48 (1.26–1.73)

1.14 (1.09–1.21)

< 0.0001

Model 2

Reference

1.07 (0.92–1.25)

1.32 (1.14–1.54)

1.42 (1.21–1.67)

1.13 (1.06–1.20)

< 0.0001

Model 3

Reference

1.08 (0.92–1.26)

1.32 (1.13–1.54)

1.42 (1.20–1.69)

1.12 (1.06–1.20)

< 0.0001

Sensitivity analysisb

Reference

1.04 (0.85–1.26)

1.42 (1.15–1.76)

1.64 (1.22–2.19)

1.18 (1.05–1.32)

< 0.0001

Sensitivity analysisc

Reference

1.02 (0.85–1.21)

1.24 (1.04–1.47)

1.42 (1.17–1.72)

1.13 (1.05–1.21)

< 0.0001

Sensitivity analysisd

Reference

1.07 (0.92–1.25)

1.32 (1.13–1.54)

1.38 (1.16–1.64)

1.12 (1.05–1.19)

< 0.0001

  1. CV coefficient of variation, SD standard deviation
  2. Model 1 adjusted for age and gender
  3. Model 2 further adjusted for body mass index, systolic blood pressure, diastolic blood pressure, fasting blood glucose, education, income, smoking status, drinking status, physical activity, history of hypertension, diabetes, and dyslipidemia
  4. Model 3 further adjusted for antihypertensive agents, hypoglycemic agents, lipid-lowering agents, estimated glomerular filtration rate, high-sensitivity C-reactive protein, baseline serum uric acid, and mean serum uric acid
  5. aIncidence rate per 1000 person-years
  6. bSensitivity analysis was excluded the participants with a hyperuricemia event at baseline or in the follow-up period, and adjusted for variables in model 3
  7. cSensitivity analysis was excluded the participants with myocardial infarction or stroke event at baseline or in the follow-up period, and adjusted for variables in model 3
  8. dSensitivity analysis was adjusted for variables in model 3 plus variability of estimated glomerular filtration rate during 2006–2010
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us